<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/082E3C1A-59C5-4E8A-BBC9-AB9D3571AE75"><gtr:id>082E3C1A-59C5-4E8A-BBC9-AB9D3571AE75</gtr:id><gtr:name>Sanford Burnham Medical Research Inst</gtr:name><gtr:address><gtr:line1>10901 North Torrey Pines Road</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FE1EC3EB-3D38-4ABB-94B2-8429AC475C8F"><gtr:id>FE1EC3EB-3D38-4ABB-94B2-8429AC475C8F</gtr:id><gtr:name>Northwestern University</gtr:name><gtr:address><gtr:line1>633 Clark Street</gtr:line1><gtr:postCode>60208</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A3C8BDDA-C539-4B60-B80C-EFD9B1165849"><gtr:id>A3C8BDDA-C539-4B60-B80C-EFD9B1165849</gtr:id><gtr:name>Salk Institute for Biological Studies</gtr:name><gtr:address><gtr:line1>Salk Institute for Biological Studies</gtr:line1><gtr:line2>PO Box 85800</gtr:line2><gtr:postCode>CA 92186 5</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:department>Immunology Infection and Inflam Diseases</gtr:department><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/082E3C1A-59C5-4E8A-BBC9-AB9D3571AE75"><gtr:id>082E3C1A-59C5-4E8A-BBC9-AB9D3571AE75</gtr:id><gtr:name>Sanford Burnham Medical Research Inst</gtr:name><gtr:address><gtr:line1>10901 North Torrey Pines Road</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FE1EC3EB-3D38-4ABB-94B2-8429AC475C8F"><gtr:id>FE1EC3EB-3D38-4ABB-94B2-8429AC475C8F</gtr:id><gtr:name>Northwestern University</gtr:name><gtr:address><gtr:line1>633 Clark Street</gtr:line1><gtr:postCode>60208</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A3C8BDDA-C539-4B60-B80C-EFD9B1165849"><gtr:id>A3C8BDDA-C539-4B60-B80C-EFD9B1165849</gtr:id><gtr:name>Salk Institute for Biological Studies</gtr:name><gtr:address><gtr:line1>Salk Institute for Biological Studies</gtr:line1><gtr:line2>PO Box 85800</gtr:line2><gtr:postCode>CA 92186 5</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/FA473957-A6EE-4164-867C-CEF3FACBFF3C"><gtr:id>FA473957-A6EE-4164-867C-CEF3FACBFF3C</gtr:id><gtr:firstName>Michael</gtr:firstName><gtr:otherNames>Henry</gtr:otherNames><gtr:surname>Malim</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G1000196"><gtr:id>0DE61102-2659-46BF-A4F5-281BF112DDC3</gtr:id><gtr:title>HIV-Host Interactions</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G1000196</gtr:grantReference><gtr:abstractText>As adult, paediatric and adolescent HIV-1 infections continue to spread worldwide, the development of further anti-retroviral treatments remains of the utmost importance; for instance, there is no effective HIV-1 vaccine, and current front-line therapies targeting the viral reverse transcriptase and protease enzymes are compromised by compliance, toxicity and viral resistance concerns. Pursuing other HIV-1 (or human) proteins as targets for future anti-virals is therefore critical, but their rational selection requires a fundamental understanding of underlying biological principles. The replication of obligate intracellular parasites, such as HIV-1, is dependent upon the contributions of many host-derived factors and pathways. However, recent work from many laboratories, including our own, has shown that host cells also produce factors that are intrinsically anti-viral and are able to antagonise virus growth. This work focuses on three aspects of the cell?s natural armoury against HIV-1. First, we will continue our investigation of human APOBEC3G/F proteins, and how they suppress infection not only by inhibiting the copying of the viral genome, but also by introducing lethal mutations. Second, we will explore the biology of APOBEC3 proteins in terms of their contributions to cell physiology, and examine the contributions of cellular factors that interact with APOBEC3 proteins (such as the RNA silencing machinery), or accumulate in similar sites with cells, to virus replication. Third, we will characterise the response of human T cells to initial invasion by HIV-1 in terms of alterations in gene expression and the potential mobilisation of anti-viral mechanisms, and compare and contrast this effects with those of the broadly anti-viral type-1 interferons. Any therapeutic strategy that stimulates these proven/potential anti-viral mechanisms has the possibility of tipping the balance between facilitatory and inhibitory activities and thereby suppressing HIV-1 infection in the context of transmission between humans or established infection. The Public Relations Dept of KCL is primarily responsible for communicating our work to the public; and a ?Directory of Experts? is maintained that enables members of the public to identify academics willing to discuss specialist areas. For instance, MHM has given numerous interviews to the press, has appeared on television and has been consulted by the BBC on the content of AIDS-related programming. He is also a Section Editor of a public access journal, PLoS Pathogens, has given overview seminars on the value of scientific research at Community Liaison Meetings (e.g., Cafe Scientifique), and helps organise Conferences attended by non-scientific members of the HIV/AIDS community.</gtr:abstractText><gtr:technicalSummary>It is now recognised that animal cells express various factors and pathways that naturally inhibit the replication of viruses. The balance between these innate/intrinsic inhibitors and the many factors that promote replication helps establish the tempo of virus infection and, ultimately, contributes to disease outcome. Here, we outline an ambitious series of discovery-based and mechanistic experiments that will continue to build on our work on the anti-HIV-1 APOBEC3G/F proteins and will explore relationships between HIV-1 infection and other potential anti-viral networks, including the RNA silencing machinery, cellular stress-induced pathways, and the type-1 interferon (IFN) system. First, we will further define the mechanisms by which the APOBEC3 proteins suppress HIV-1 infection. In particular, we will determine how APOBEC3 proteins inhibit HIV-1 reverse transcription in primary CD4 T cells, using new assays to define the cDNAs of inhibited replication intermediates, to map interactions between APOBEC3G/F proteins and viral proteins and RNA, and to define the necessary participating attributes of the APOBEC3G/F proteins. Second, having demonstrated that APOBEC3G/F assemble into large cellular ribonucleoprotein (RNP) complexes, we will define the RNAs to which these proteins bind directly and address the impact of such interactions upon RNA fate and metabolism. Since APOBEC3G/F RNPs accumulate in RNA-rich cellular microdomains called P bodies (PBs) and stress granules (SGs), and some of the factors and complexes that also accumulate there (e.g., the RNA silencing machinery) have been implicated in the suppression of viral and transposon replication, we will investigate the importance of PB-, SG- or RNA silencing components in HIV-1 replication and APOBEC3G/F function. Third, we will use transcriptomic-based methodologies to define the initial (i.e., within hrs) response of CD4 T cells to HIV-1 challenge. Our preliminary results indicate that cells undergo substantial reprogramming, and that many of the induced host genes are also activated by type-1 IFN. Functional analyses will aim to identify cellular sensors of HIV-1 infection, as well as downstream signalling pathways and effector molecules. This work will be interpreted together with parallel studies where the mechanism by which IFN establishes an anti-HIV-1 state in T cells and macrophages is examined, and screens to isolate the contributing genes are undertaken. In sum, we aim to identify novel interactions between HIV-1 and infected host cells, with the goal of better understanding the principles of virus replication, pathogenesis and human cell biology, as well as defining rational targets for future therapeutic exploitation.</gtr:technicalSummary><gtr:fund><gtr:end>2016-04-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-11-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1775866</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Biomedical Sciences KCL</gtr:department><gtr:description>King's College London, Randall Division</gtr:description><gtr:id>10382323-1C07-46D3-B545-13BB81EDBFE5</gtr:id><gtr:impact>PMID: 20532212, 24225024</gtr:impact><gtr:outcomeId>PYF1pR8mN7S-1</gtr:outcomeId><gtr:partnerContribution>We collaborated on structural biology projects concerning APOBEC3G, HIV-1 Vif and the cullin5/elonginBC E3 ubiquitin ligase complex</gtr:partnerContribution><gtr:piContribution>I was a co-investigator on a Wellcome Trust grant, &amp;quot;Structural and biochemical studies on the interaction of HIV-1 Vif with its partner ubiquitin ligase complex&amp;quot;. The other investigator was Dr Mark Sanderson. We provided DNA constructs, as well as biochemical and virological expertise.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Northwestern University Chicago</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Northwestern University, Chicago</gtr:description><gtr:id>78E39CB5-E8D5-4F14-9A2C-F8F512AB48BA</gtr:id><gtr:impact>PMID: 19057663, 19587057, 20660203, 21697957, 22727223, 22915799, 23152537</gtr:impact><gtr:outcomeId>CFmcrce8yQS-1</gtr:outcomeId><gtr:partnerContribution>We collaborate on a number of projects addressing the contributions of APOBEC3 proteins to HIV transmission, pathogenesis following transmission, and viral sequence evolution.</gtr:partnerContribution><gtr:piContribution>I was a co-investigator on an NIH grant (AI070072), &amp;quot;The APOBEC/Vif Conflict and HIV Pathogenesis&amp;quot;. The lead PI is Dr Steve Wolinsky. The project addressed the contributions of APOBEC3 proteins to HIV transmission, pathogenesis following transmission, and viral sequence evolution. Our groups work together on various projects in this area, and members of my lab have undertaken short sabbaticals at Northwestern to learn new techniques.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sanford-Burnham Medical Research Institute</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>HIV Immune Networks Team (HINT)</gtr:description><gtr:id>D94A7AFE-2A9B-480B-A5AE-D2BF0EDE708F</gtr:id><gtr:impact>A grant application entitled &amp;quot;A systems-level approach to studying HIV/AIDS susceptibility and substance abuse&amp;quot; has been submitted to the National Institute on Drug Abuse (NIDA)</gtr:impact><gtr:outcomeId>WVdfKooWk2s-3</gtr:outcomeId><gtr:partnerContribution>The Network contributes data, ideas and collaborative experiments regarding HIV-1 infection, and its control</gtr:partnerContribution><gtr:piContribution>We contribute data and ideas concerning the interactions between HIV-1 infection and innate immunity, focusing particularly on type 1 interferon.
I am a co-investigator on an NIH grant (DA033773) together with Steven M. Wolinsky (lead PI), Sumit K. Chandra, Adolfo Garc&amp;iacute;a-Sastra, Nevan J. Krogan &amp;amp; John A.T. Young, &amp;quot;A systems-level approach to studying HIV/AIDS susceptibility and substance abuse&amp;quot;. This supports aspects of HINT's research agenda</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Northwestern University Chicago</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>HIV Immune Networks Team (HINT)</gtr:description><gtr:id>A751B0A9-7FF8-4CAC-832E-CC8B8F24A71F</gtr:id><gtr:impact>A grant application entitled &amp;quot;A systems-level approach to studying HIV/AIDS susceptibility and substance abuse&amp;quot; has been submitted to the National Institute on Drug Abuse (NIDA)</gtr:impact><gtr:outcomeId>WVdfKooWk2s-1</gtr:outcomeId><gtr:partnerContribution>The Network contributes data, ideas and collaborative experiments regarding HIV-1 infection, and its control</gtr:partnerContribution><gtr:piContribution>We contribute data and ideas concerning the interactions between HIV-1 infection and innate immunity, focusing particularly on type 1 interferon.
I am a co-investigator on an NIH grant (DA033773) together with Steven M. Wolinsky (lead PI), Sumit K. Chandra, Adolfo Garc&amp;iacute;a-Sastra, Nevan J. Krogan &amp;amp; John A.T. Young, &amp;quot;A systems-level approach to studying HIV/AIDS susceptibility and substance abuse&amp;quot;. This supports aspects of HINT's research agenda</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Salk Institute for Biological Studies</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>HIV Immune Networks Team (HINT)</gtr:description><gtr:id>873ED58E-3CC1-4C7F-943A-E108BBCBE5BB</gtr:id><gtr:impact>A grant application entitled &amp;quot;A systems-level approach to studying HIV/AIDS susceptibility and substance abuse&amp;quot; has been submitted to the National Institute on Drug Abuse (NIDA)</gtr:impact><gtr:outcomeId>WVdfKooWk2s-2</gtr:outcomeId><gtr:partnerContribution>The Network contributes data, ideas and collaborative experiments regarding HIV-1 infection, and its control</gtr:partnerContribution><gtr:piContribution>We contribute data and ideas concerning the interactions between HIV-1 infection and innate immunity, focusing particularly on type 1 interferon.
I am a co-investigator on an NIH grant (DA033773) together with Steven M. Wolinsky (lead PI), Sumit K. Chandra, Adolfo Garc&amp;iacute;a-Sastra, Nevan J. Krogan &amp;amp; John A.T. Young, &amp;quot;A systems-level approach to studying HIV/AIDS susceptibility and substance abuse&amp;quot;. This supports aspects of HINT's research agenda</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>251928</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research Training Fellowship (for Medical Graduates) for Chris Ward</gtr:description><gtr:end>2017-06-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:fundingRef>103407/Z/13/Z</gtr:fundingRef><gtr:id>D0980DAE-3815-4058-9EB6-2D7D6DE97DEC</gtr:id><gtr:outcomeId>5448fa9e384912.40494532</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>365006</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>R01 (USA)</gtr:description><gtr:end>2017-03-02</gtr:end><gtr:fundingOrg>National Institutes of Health (NIH)</gtr:fundingOrg><gtr:fundingRef>DA033773</gtr:fundingRef><gtr:id>275CACE0-FB17-42E2-B6E8-BACD575F55AB</gtr:id><gtr:outcomeId>bVPBiW4Rkwb</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>229617</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research Training Fellowship (for Medical Graduates)</gtr:description><gtr:end>2015-10-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:fundingRef>098850/Z/12/Z</gtr:fundingRef><gtr:id>D6A78524-D7B0-4D8B-A62C-F361EB59D1FA</gtr:id><gtr:outcomeId>JvFX9S38UWN</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1822984</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Wellcome Trust Senior Investigator Award</gtr:department><gtr:description>Wellcome Trust Senior Investigator</gtr:description><gtr:end>2020-03-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:fundingRef>106223/Z/14/Z</gtr:fundingRef><gtr:id>CFCBF232-9617-45B3-ACE2-C56B21CFB4A9</gtr:id><gtr:outcomeId>56b88bcdbaedd4.39108455</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2015-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>175311</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Marie Curie Intra-European Fellowship for Dr Darja Pollpeter</gtr:description><gtr:end>2015-03-02</gtr:end><gtr:fundingOrg>Marie Sklodowska-Curie Actions</gtr:fundingOrg><gtr:id>23E66E90-5FA8-4FA8-BFF6-F8C4FBD25A7D</gtr:id><gtr:outcomeId>5448f806499876.32872399</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Expression vectors for HIV proteins, cellular proteins, as well as tagged and mutated derivatives thereof have been constructed in a variety of plasmid- and retrovirus-based vectors</gtr:description><gtr:id>78FA413F-3720-4997-9067-7D6C4C23226D</gtr:id><gtr:impact>The work on APOBEC proteins as natural inhibitors of HIV/SIV infection has founded new fields of research, not only on these proteins but, more broadly, on cell-based mechanisms of virus resistance (TRIM, tetherin, etc). Much of this work relies on reagents such as those developed in this lab.</gtr:impact><gtr:outcomeId>859E5BC90B7</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Expression vectors for HIV- or cell-encoded proteins</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>A variety of human and primate cell lines expressing wild type or mutated human APOBEC3 proteins have been constructed</gtr:description><gtr:id>8A2E6064-A1AE-4B1E-B2AB-E3E0079C6B24</gtr:id><gtr:impact>basic research findings</gtr:impact><gtr:outcomeId>4C9668CB6BB</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>APOBEC3 protein expressing cell lines</gtr:title><gtr:type>Cell line</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>inducible lentivirus vector system</gtr:description><gtr:id>C94D8C8F-41B4-4BB9-962A-7C46A143CCBF</gtr:id><gtr:impact>useful tool for gene discovery and analysis</gtr:impact><gtr:outcomeId>56b88e48e76727.26115299</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>EasiLV</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>51BDEF2A-37E4-41B6-8A7C-978BF8DD13F2</gtr:id><gtr:title>Rationalisation of the differences between APOBEC3G structures from crystallography and NMR studies by molecular dynamics simulations.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2d69104c0b0ec4d119bba9dd531cd524"><gtr:id>2d69104c0b0ec4d119bba9dd531cd524</gtr:id><gtr:otherNames>Autore F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>1EEE9F47A30</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7E5FC07E-F5D2-481C-9011-D4F361750D00</gtr:id><gtr:title>Characterization of the alpha interferon-induced postentry block to HIV-1 infection in primary human macrophages and T cells.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/74a0ff0ef24bc64a468e4f87b0b43c0b"><gtr:id>74a0ff0ef24bc64a468e4f87b0b43c0b</gtr:id><gtr:otherNames>Goujon C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>iLxRe4shftf</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F576241B-3FC1-4EC9-82C5-936FA563B505</gtr:id><gtr:title>HIV Restriction Factors and Mechanisms of Evasion.</gtr:title><gtr:parentPublicationTitle>Cold Spring Harbor perspectives in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/08cdaef89f33d6b94fb92520b444ffcf"><gtr:id>08cdaef89f33d6b94fb92520b444ffcf</gtr:id><gtr:otherNames>Malim MH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>2157-1422</gtr:issn><gtr:outcomeId>pm_14565_25_22553496</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E9E59D01-7730-4041-BCBF-E1A0A65DA893</gtr:id><gtr:title>Human MX2 is an interferon-induced post-entry inhibitor of HIV-1 infection.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/74a0ff0ef24bc64a468e4f87b0b43c0b"><gtr:id>74a0ff0ef24bc64a468e4f87b0b43c0b</gtr:id><gtr:otherNames>Goujon C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>pm_14565_25_24048477</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DE36C54B-E209-485F-88E6-BA6F6CC331F8</gtr:id><gtr:title>Evidence for IFNa-induced, SAMHD1-independent inhibitors of early HIV-1 infection.</gtr:title><gtr:parentPublicationTitle>Retrovirology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/74a0ff0ef24bc64a468e4f87b0b43c0b"><gtr:id>74a0ff0ef24bc64a468e4f87b0b43c0b</gtr:id><gtr:otherNames>Goujon C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1742-4690</gtr:issn><gtr:outcomeId>pm_14565_25_23442224</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FB4A0103-79B5-4079-8433-61DA023DD7BE</gtr:id><gtr:title>Evolution of a species-specific determinant within human CRM1 that regulates the post-transcriptional phases of HIV-1 replication.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a84d7fc0c78b0b04b5b583554dc7ff07"><gtr:id>a84d7fc0c78b0b04b5b583554dc7ff07</gtr:id><gtr:otherNames>Sherer NM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>EQvYXK9uqVQ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E9A20A4A-3618-4FA2-81A5-D7BC8681C121</gtr:id><gtr:title>Oligomerization Requirements for MX2-Mediated Suppression of HIV-1 Infection.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f1e863e501dee503acf8b635e2154529"><gtr:id>f1e863e501dee503acf8b635e2154529</gtr:id><gtr:otherNames>Dicks MD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>56b88a5d129523.46899657</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>828A9E9D-1FF3-4B96-B1E6-202C79086A2D</gtr:id><gtr:title>Nuclear import of SAMHD1 is mediated by a classical karyopherin a/?1 dependent pathway and confers sensitivity to VpxMAC induced ubiquitination and proteasomal degradation.</gtr:title><gtr:parentPublicationTitle>Retrovirology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2b80e4206e65c27027c5eb4c5816ed08"><gtr:id>2b80e4206e65c27027c5eb4c5816ed08</gtr:id><gtr:otherNames>Schaller T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1742-4690</gtr:issn><gtr:outcomeId>5448f3683f8cd4.51945801</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>537C15C6-053E-4B23-BE9E-D35FC6BF59E5</gtr:id><gtr:title>Insight into the HIV-1 Vif SOCS-box-ElonginBC interaction.</gtr:title><gtr:parentPublicationTitle>Open biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4b6bba42ade1380857ec0ebbc773da57"><gtr:id>4b6bba42ade1380857ec0ebbc773da57</gtr:id><gtr:otherNames>Lu Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2046-2441</gtr:issn><gtr:outcomeId>5448f30347cfa2.96562727</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C61D40CA-A264-4CF1-870C-B2EC09CF2899</gtr:id><gtr:title>Effects of Inner Nuclear Membrane Proteins SUN1/UNC-84A and SUN2/UNC-84B on the Early Steps of HIV-1 Infection.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2b80e4206e65c27027c5eb4c5816ed08"><gtr:id>2b80e4206e65c27027c5eb4c5816ed08</gtr:id><gtr:otherNames>Schaller T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>5a8aaff513a7a9.12519965</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EE2FF344-81D4-4EB7-BC5E-C93985FCEDB7</gtr:id><gtr:title>The innate antiviral factor APOBEC3G targets replication of measles, mumps and respiratory syncytial viruses.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6129759e49f00144c4b8d4ff35f27a1a"><gtr:id>6129759e49f00144c4b8d4ff35f27a1a</gtr:id><gtr:otherNames>Fehrholz M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>pm_14565_25_22170635</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F71E03AE-BF61-4CBA-A782-D95D2C3EFE4D</gtr:id><gtr:title>Persistent HIV-1 replication maintains the tissue reservoir during therapy.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3f0fd5633fe9873af7189b5c76e3c29a"><gtr:id>3f0fd5633fe9873af7189b5c76e3c29a</gtr:id><gtr:otherNames>Lorenzo-Redondo R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>56b88ac50e34b5.99072231</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>879CB66F-4D6C-4714-AF5D-ECB01315AB16</gtr:id><gtr:title>Endogenous MOV10 inhibits the retrotransposition of endogenous retroelements but not the replication of exogenous retroviruses.</gtr:title><gtr:parentPublicationTitle>Retrovirology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/01aac83b8549060d77dffdc6ae1fd282"><gtr:id>01aac83b8549060d77dffdc6ae1fd282</gtr:id><gtr:otherNames>Arjan-Odedra S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1742-4690</gtr:issn><gtr:outcomeId>pm_14565_25_22727223</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E92131EC-6A7D-4CF2-8846-3B837C44D433</gtr:id><gtr:title>AIDS/HIV. HIV interplay with SAMHD1.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2b80e4206e65c27027c5eb4c5816ed08"><gtr:id>2b80e4206e65c27027c5eb4c5816ed08</gtr:id><gtr:otherNames>Schaller T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn><gtr:outcomeId>pm_14565_25_22422971</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>96A955BA-A9FB-4941-9BFF-0D29355844CF</gtr:id><gtr:title>A triple-arginine motif in the amino-terminal domain and oligomerization are required for HIV-1 inhibition by human MX2.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/74a0ff0ef24bc64a468e4f87b0b43c0b"><gtr:id>74a0ff0ef24bc64a468e4f87b0b43c0b</gtr:id><gtr:otherNames>Goujon C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>56b889c398a345.18694134</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>01017464-045B-4B72-A40B-B33389C4D07F</gtr:id><gtr:title>Human APOBEC3G-mediated editing can promote HIV-1 sequence diversification and accelerate adaptation to selective pressure.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/acad78882d25f801f5874af5ec73f5a4"><gtr:id>acad78882d25f801f5874af5ec73f5a4</gtr:id><gtr:otherNames>Kim EY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>Yz4RpFTnZKG</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E0E144F8-D6F4-4B5C-97E7-058FA75883B1</gtr:id><gtr:title>Gold nanoparticle-mediated gene delivery induces widespread changes in the expression of innate immunity genes.</gtr:title><gtr:parentPublicationTitle>Gene therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/acad78882d25f801f5874af5ec73f5a4"><gtr:id>acad78882d25f801f5874af5ec73f5a4</gtr:id><gtr:otherNames>Kim EY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0969-7128</gtr:issn><gtr:outcomeId>F59vZxLuu2P</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E21B3CE7-B111-41EA-BE98-2C7F6DF75F0E</gtr:id><gtr:title>Human APOBEC3 induced mutation of human immunodeficiency virus type-1 contributes to adaptation and evolution in natural infection.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/acad78882d25f801f5874af5ec73f5a4"><gtr:id>acad78882d25f801f5874af5ec73f5a4</gtr:id><gtr:otherNames>Kim EY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>5448f3d5d1b452.75582824</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BFE5D421-0704-4FC3-907B-CFCC98DAD84E</gtr:id><gtr:title>Transfer of the amino-terminal nuclear envelope targeting domain of human MX2 converts MX1 into an HIV-1 resistance factor.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/74a0ff0ef24bc64a468e4f87b0b43c0b"><gtr:id>74a0ff0ef24bc64a468e4f87b0b43c0b</gtr:id><gtr:otherNames>Goujon C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>5448f3b5630780.23820469</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>75E5D470-80BE-41E3-81E9-3D4A36C1B3FA</gtr:id><gtr:title>Suppression of HIV-1 infection by APOBEC3 proteins in primary human CD4(+) T cells is associated with inhibition of processive reverse transcription as well as excessive cytidine deamination.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2d0081983a84256e14922a086b8b9919"><gtr:id>2d0081983a84256e14922a086b8b9919</gtr:id><gtr:otherNames>Gillick K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>pm_14565_25_23152537</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A15A4734-83EB-4AFB-85B7-EAFBB1FBAD49</gtr:id><gtr:title>HIV-1 replication and APOBEC3 antiviral activity are not regulated by P bodies.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c289ea9f855e7d4ef862dedff62b35b1"><gtr:id>c289ea9f855e7d4ef862dedff62b35b1</gtr:id><gtr:otherNames>Phalora PK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>pm_14565_25_22915799</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6A3825DF-B6E4-408F-81CF-D14B8A3F65A3</gtr:id><gtr:title>HIV: Ringside views.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/08cdaef89f33d6b94fb92520b444ffcf"><gtr:id>08cdaef89f33d6b94fb92520b444ffcf</gtr:id><gtr:otherNames>Malim MH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>5448f336969413.73910251</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A3F631F5-F65F-4894-A17E-8589ABEEF40F</gtr:id><gtr:title>HIV-1 and interferons: who's interfering with whom?</gtr:title><gtr:parentPublicationTitle>Nature reviews. Microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68ef4bc924b19c7e189b6f654810964e"><gtr:id>68ef4bc924b19c7e189b6f654810964e</gtr:id><gtr:otherNames>Doyle T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1740-1526</gtr:issn><gtr:outcomeId>56b88a0ca42b54.41736026</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0C717AB1-9269-49EB-ABB6-FD283A542641</gtr:id><gtr:title>Deep sequencing of HIV-1 reverse transcripts reveals the multifaceted antiviral functions of APOBEC3G.</gtr:title><gtr:parentPublicationTitle>Nature microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5939f54072d349693fe420118dda80db"><gtr:id>5939f54072d349693fe420118dda80db</gtr:id><gtr:otherNames>Pollpeter D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>2058-5276</gtr:issn><gtr:outcomeId>5a8ab026344bf8.67337894</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F36A40F7-E3B3-4CDF-972E-E6B200DC225A</gtr:id><gtr:title>Immune evasion activities of accessory proteins Vpu, Nef and Vif are conserved in acute and chronic HIV-1 infection.</gtr:title><gtr:parentPublicationTitle>Virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/292b41fa56f474420b9e8bde21def9a9"><gtr:id>292b41fa56f474420b9e8bde21def9a9</gtr:id><gtr:otherNames>Mlcochova P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0042-6822</gtr:issn><gtr:outcomeId>5675e1961a9f1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B0D887C2-BF3E-4EAA-935D-FC5834014C2D</gtr:id><gtr:title>Cooperativity among Rev-associated nuclear export signals regulates HIV-1 gene expression and is a determinant of virus species tropism.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/50144aa725fb847b17f9a2c310811208"><gtr:id>50144aa725fb847b17f9a2c310811208</gtr:id><gtr:otherNames>Aligeti M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>5448f3f467dde6.92876702</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C1BFE655-B5E0-4375-988B-4CFA43B7C10E</gtr:id><gtr:title>Promiscuous RNA binding ensures effective encapsidation of APOBEC3 proteins by HIV-1.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3f3a76b86c1f9a984be4d45a8faa279a"><gtr:id>3f3a76b86c1f9a984be4d45a8faa279a</gtr:id><gtr:otherNames>Apolonia L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>doi_55faa2aa20c8fb2d</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6CB020B4-5271-455C-9E78-397E3EF5FFBC</gtr:id><gtr:title>New insights into an X-traordinary viral protein.</gtr:title><gtr:parentPublicationTitle>Frontiers in microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2b80e4206e65c27027c5eb4c5816ed08"><gtr:id>2b80e4206e65c27027c5eb4c5816ed08</gtr:id><gtr:otherNames>Schaller T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1664-302X</gtr:issn><gtr:outcomeId>5448f38c7469a6.43823278</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3678EBD4-B8A3-4B59-99B5-BDB98FE902DE</gtr:id><gtr:title>Target cell-mediated editing of HIV-1 cDNA by APOBEC3 proteins in human macrophages.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e7ffd30d3d558be5c0122ed5a8f57f0"><gtr:id>8e7ffd30d3d558be5c0122ed5a8f57f0</gtr:id><gtr:otherNames>Koning FA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>cJB7RK6bzJ1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>53461E01-809B-496D-BF98-96729C56037F</gtr:id><gtr:title>How Representative Are Research Tissue Biobanks of the Local Populations? Experience of the Infectious Diseases Biobank at King's College, London, UK.</gtr:title><gtr:parentPublicationTitle>Biopreservation and biobanking</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/25ebe5f248f4ee7e04bf269bf8085d97"><gtr:id>25ebe5f248f4ee7e04bf269bf8085d97</gtr:id><gtr:otherNames>Kozlakidis Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1947-5543</gtr:issn><gtr:outcomeId>NW9WNkjZ6rM</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0FBEECED-07EF-4C17-8008-F5298CA206F6</gtr:id><gtr:title>Complex Interplay between HIV-1 Capsid and MX2-Independent Alpha Interferon-Induced Antiviral Factors.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4198d352b1b17d1224037c3ac01ff63c"><gtr:id>4198d352b1b17d1224037c3ac01ff63c</gtr:id><gtr:otherNames>Bulli L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>585d3a8fc75e08.48556859</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1000196</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>